CD-ROM

Viral resistance testing in clinical trials and practice

Presentation type		Track	Abstract category	Text
All Oral abstracts Poster Discussions Poster Exhibition CD-ROM		All A B C D	All Acute and early infection Acute and early infection and management of patients with acquired viral resistance Adherence in adults Adherence in children and adolescents Ageing AIDS related malignancies (KS, lymphoma, cervical and anal carcinoma) including HHV8 infection Animal Models Animal models of transmission, disease resistance and progression Antibody based vaccines Antiretroviral Therapies (strategic categories apply to resource rich and constrained settings) in Children and Adolescents Antiretroviral therapy,clinical trials and cohorts Antiretroviral treatment of people living with HIV for prevention Approaches to counselling and testing in children and caregivers Behavioural surveillance Bioinformatic analysis in drug resistance Bioinformatics analysis of viral diversity in natural history Blood, organ and tissue safety and nosocomial transmission Cellular immunity based vaccines Clinical trials Cohort studies Complementary and traditional medicines and the role of traditional healers in therapy Complications of Anti-Retroviral Therapy and Adherence in Adults and Children Correlates of immune protection Diagnosis of HIV disease Diagnostic Tools for the Immunological and Virological Monitoring of HIV Infection Disease burden – morbidity/mortality Epidemiology of HIV in people who use drugs Epidemiology of sexually transmitted infections (STI) and HIV Estimating the need for HIV treatment Estimating the size of HIV-infected and most at risk population Ethical issues in epidemiological research First line therapy Harm reduction, including reduction of unsafe injecting and other approaches Hepatitis co-infections: (including HBV, HCV) HIV counselling, testing and diagnostic strategies HIV diversity and epidemiology HIV Pathogenesis/Immune Function and Dysfunction HIV Pathogenesis/Latency and Viral Reservoirs HIV superinfections HIV Surveillance, Monitoring and Evaluation HIV tropism, dynamics and fitness HIV-1 and HIV-2 co-infections HIV-2 Host genetics of resistance and susceptibility Immune reconstitution disorders / IRIS Impact of nutrition Innate immunity responses and function in natural history of HIV infection Malaria Male and female condoms and other physical barriers Male circumcision Management of late presenters Measuring and modelling the effect and impact of other HIV prevention interventions Measuring and modelling the effect and impact of PMTCT Measuring and modelling the impact of the HIV epidemic Mechanisms of T cell depletion and dysfunction Methodological Issues and Capacity-Building in Epidemiology and Prevention Research Microbicides Monitoring and evaluation (other) Monitoring and evaluation of HIV prevention, care and treatment Mother to child transmission Mucosal immunity/defenses: responses and dysfunction Mucosal transmission Mycobacteria and TB Natural history, progression and survival Neurologic and psychiatric manifestations, including neurocognitive disorders New HIV testing and diagnostic strategies New monitoring strategies including rapid tests Non pathogenic models of SIV Non-AIDS related co-morbidities (e.g. diabetes, hypertension etc) Non-AIDS related malignancies Novel animal models for vaccine and inhibitor development Novel assays of immune responses Novel Treatment and Prevention Strategies Novel vectors and strategies Nucleic acid based HIV and SIV therapies Opportunistic infections (excluding mycobacterial) Other adverse reactions and complications of ARV therapy Other bacterial infections and malaria and parasitic infections Other complications Other Therapies Paediatric surveillance of HIV Pharmacogenomics Pharmacology, pharmacokinetics, drug formulations Population-based surveys with HIV testing Preclinical development of microbicides Pre-exposure and post-exposure prophylaxis Prevention addressing gender inequalities Prevention for men who have sex with men (MSM) Prevention for people living with HIV Prevention for people who use drugs Prevention for the general population Prevention in institutional settings e.g. workplace, school, prison, military Prevention of mother-to-child transmission Prophylaxis of HIV associated infections; vaccines e.g. pneumococcal, hepatitis and HPV, co-trimoxazole prophylaxis and IPT Research designs in epidemiology Sexually transmitted infections (STI) Simplification strategies (induction/maintenance and use of bPI monotherapy) STI prevention and control Surveillance of HIV (Youth and Adults) Surveillance systems and methods Switch studies Therapy for the heavily pre-treated patient Track B - Clinical Sciences Track C: Epidemiology and Prevention Sciences Transmission and Early Infection Tuberculosis Viral determinants of SIV pathogenesis Viral fitness and tropism assays, utility and application in clinical practice Viral resistance testing in clinical trials and practice Virus-specific cellular immunity When to start therapy
Late breakers only

Posters with this symbol have been selected by the Scientific Programme Committee for distinction based on merit.

Posters with this symbol have an e-Poster available.

CDB020 Abstract Drug resistance among HIV-infected patients in Hochiminh, Vietnam T.T.X. Lien, T. Tran, H.H.K. Thu, L.T. Tram, L.C. Thanh, T.C. Thanh, P.D. Quang, Pasteur Institute in Ho Chi Minh City, Vietnam Pasteur Institute, HIV/AIDS Laboratory, Ho Chi Minh City, Viet Nam CDB021 Abstract Agreement degree between two genotype interpretation systems, tipranavir (TPV) and darunavir (DRV) validated weighted scores (WS) and Stanford HIVdb program M.J. Pérez Elías1, C. Gutierrez1, J.L. Casado1, A. Moreno1, D. Lopez1, E. Delsol1, D. Fernando1, I. Garcia-Arata2, A. Muriel3, E. Garcia3, B. Hernandez1, M.A. Rodriguez3, J.C. Galan3, S. Moreno1 1Hospital Ramón y Cajal, Infectious Diseases, Madrid, Spain, 2Hospital de Fuenlabrada, Madrid, Spain, 3Hospital Ramon y Cajal, Madrid, Spain CDB022 Abstract Genotypic resistance mutations in treatment-naïve and treatment-experienced patients Y.J. Kim, S.I. Kim, S.H. Wie, Y.R. Kim, M.W. Kang Seoul St. Mary's Hospital,The Catholic University of Korea, Internal Medicine, Seoul, Korea, Republic of CDB023 Abstract Generation of HIV-1 subtype C recombinant viruses for phenotypic analysis of protease and reverse transcriptase inhibitor resistance profiles D. Nauwelaers1, M. Van Houtte2, K. Steegen1, B. Winters2, L.J. Stuyver1 1Virco BVBA, Virco R&D, Mechelen, Belgium, 2Virco BVBA, Clinical Virology, Mechelen, Belgium CDB024 Abstract High efficacy of more than two active antiretroviral drugs including ETV in HIV-1 infected patients with high antiretroviral experience J.R. Santos, J.M. Llibre, J. Moltó, P. Cobarsi, I. Bravo, B. Clotet Lluita contra la Sida Foundation, Hospital Universitari Germans Trias i Pujol, Badalona, Spain CDB025 Abstract Long-term resistance monitoring in HAART experienced patients in Argentina M.I. Figueroa1, M. Carobene2, A. Rubio3, F. Moretti3, R. Tejeiro3, P. Cahn1,4, H. Salomon3 1Hospital J. A. Fernández, Ciudad autonoma de Buenos Aires, Argentina, 2National Reference Center for AIDS, Microbiology. School of Medicine. University of Buenos Aires, Ciudad de Buenos Aires, Argentina, 3National Reference Center for AIDS, Microbiology. School of Medicine. University of Buenos Aires, Ciudad autonoma de Buenos Aires, Argentina, 4Área de Investigaciones clínicas de la Fundación Huesped, Ciudad de Buenos Aires, Argentina CDB026 Abstract Determination of drug resistance in rural South Africa L.G. Mavhandu1,2, H. Cheng2, Y.-C. Bor2, W. Yuan2, J. Mphahlele3, P.O. Bessong1, M.-L. Hammarskjold2, D. Rekosh2 1University of Venda, Microbiology, Thohoyandou, South Africa, 2University of Virginia, Myles H. Thaler Center for AIDS and Human Retrovirus Research and The Center for Global Health, Charlottesville, United States, 3University of Limpopo, Medunsa Campus, Department of Medical Virology, Garankuwa, South Africa CDB027 Abstract Cost effectiveness of international shipment of dried plasma for HIV resistance testing C. Loveday1, Z. Grossman2, R. Lloyd3, D. Burns3, R. Mathis3, J. Cooper3, M. Holodniy4 1ICVC Charitable Trust, Buckinghamshire, United Kingdom, 2Sheba Medical Center, Tel-Hashomer, Israel, 3Research ThinkTank, Atlanta, United States, 4VA Palo Alto Health Care System, Palo Alto, United States CDB028 Abstract Unusual deletion at codon 70 of HIV-1 subtype C reverse transcriptase from first-line HAART failing South Indian patients V. Madhavan1, S. Shanmugam1, U. Shanmugasundaram1, K. Rami2, K. Nagalingeswaran1, B. Ramratnam2, S.S. Solomon1, S. Solomon1, K.H. Mayer2, D. Katzenstein3, B. Pachamuthu1 1Y R Gaitonde Centre for AIDS Research and Education (YRGCARE), Chennai, India, 2Brown University, Providence, United States, 3Stanford University, Palo Alto, United States CDB029 Abstract Factors associated with increasing HIV-1 resistance to antiretroviral therapy in an urban cohort in Kampala, Uganda H. Sendagire1, B. Castelnuovo1, A. Kiragga1, A. Kambugu1, M. Kamya1, P. Easterbrook2, Y. Manabe1,3, E. Arts4, T. Quinn3,5, S. Reynolds3,5 1Infectious Diseases Institute, Makerere University, Kampala, Uganda, 2Kings College, London, United Kingdom, 3Johns Hopkins University, School of Medicine, Baltimore, United States, 4Case Western Reserve University, Cleveland, United States, 5National Institute for Allergy and Infectious Diseases, National Institutes of Health, Bethesda, United States